Progress in the pharmacogenomics of the oral anticoagulant agent warfarin

The oral anticoagulant warfarin has a narrow therapeutic range and wide inter-individual dosing requirements,genetic factors together with several non-genetic patient-specific factors are important determinants of stable dose requirement for the agent.Genotype for CYP2C9 and vitamin K epoxide reductase complex subunit(1-VKORC1),which encodes the main functional variants of genes affecting warfarin metabolism and activity,were widely investigated.We reviewed some literatures about pharmacogenomics of warfarin,that may help clinicians to give individualized therapy on patients,and minimize adverse drug reaction such as bleeding.